Heidi Kabler

1.4k total citations · 1 hit paper
11 papers, 471 citations indexed

About

Heidi Kabler is a scholar working on Epidemiology, Infectious Diseases and Health. According to data from OpenAlex, Heidi Kabler has authored 11 papers receiving a total of 471 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Epidemiology, 3 papers in Infectious Diseases and 2 papers in Health. Recurrent topics in Heidi Kabler's work include Influenza Virus Research Studies (4 papers), Pneumonia and Respiratory Infections (3 papers) and Antimicrobial Resistance in Staphylococcus (3 papers). Heidi Kabler is often cited by papers focused on Influenza Virus Research Studies (4 papers), Pneumonia and Respiratory Infections (3 papers) and Antimicrobial Resistance in Staphylococcus (3 papers). Heidi Kabler collaborates with scholars based in United States, Canada and Switzerland. Heidi Kabler's co-authors include J. Scott Overcash, Samantha Good, Greg Moeck, William O’Riordan, Hai Jiang, Purvi Mehra, Christopher Lucasti, Sandeep K. Gupta, Antonio L. Pérez and Ashwin Porwal and has published in prestigious journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Heidi Kabler

10 papers receiving 451 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial

2022 157 citations Naim Alkhouri, Robert Herring et al. Journal of Hepatology profile →

Peers

Heidi Kabler

EPIDE

PHEOH

PHARM

Onur Kaya Türkiye

J. Scott Overcash United States

Ana María Sánchez‐Díaz Spain

Hai Jiang China

Charlotte M. Harvey United States

Dong Hoon Shin South Korea

Marie Françoise Tripodi Italy

E. S. Kim South Korea

Duncan R Cranendonk Netherlands

Jennifer Villa Spain

Onur Kaya Türkiye

Heidi Kabler

123 ×0.6

150 ×0.9

EPIDE

36 ×0.3

27 ×0.3

PHEOH

34 ×0.4

PHARM

Citations per year, relative to Heidi Kabler Heidi Kabler (= 1×) peers Onur Kaya

Countries citing papers authored by Heidi Kabler

Since Specialization

Citations

This map shows the geographic impact of Heidi Kabler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Kabler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Kabler more than expected).

Fields of papers citing papers by Heidi Kabler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heidi Kabler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Kabler. The network helps show where Heidi Kabler may publish in the future.

Co-authorship network of co-authors of Heidi Kabler

This figure shows the co-authorship network connecting the top 25 collaborators of Heidi Kabler. A scholar is included among the top collaborators of Heidi Kabler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heidi Kabler. Heidi Kabler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Hsiao, Amber, Ruvim Izikson, Bruce Fireman, et al.. (2024). Safety of quadrivalent recombinant influenza vaccine in pregnant persons and their infants. AJOG Global Reports. 4(4). 100395–100395. 2 indexed citations

Gadbois, Emily A., Amy Meehan, Rosa Baier, et al.. (2023). Identifying strategies that promote staff and resident influenza and COVID-19 vaccination in nursing homes: Perspectives from nursing home staff. Geriatric Nursing. 54. 205–210. 2 indexed citations

Mahmud, Salaheddin M., Christiaan H. Righolt, Geng Zhang, et al.. (2023). Regional Disparities in the Uptake of Differentiated Influenza Vaccines in the United States. Journal of Racial and Ethnic Health Disparities. 12(1). 320–325.

Alkhouri, Naim, Robert Herring, Heidi Kabler, et al.. (2022). Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. Journal of Hepatology. 77(3). 607–618. 157 indexed citations breakdown →

Yu, Kalvin, et al.. (2022). A multicenter analysis of inpatient antibiotic use during the 2015–2019 influenza seasons in the United States: Untapped opportunities for antimicrobial stewardship. SHILAP Revista de lepidopterología. 2(1). e140–e140. 1 indexed citations

Meehan, Amy, Emily A. Gadbois, Rosa Baier, et al.. (2022). Impact of COVID ‐19 on influenza and infection control practices in nursing homes. Journal of the American Geriatrics Society. 71(2). 661–665. 3 indexed citations

Gupta, Vikas, et al.. (2022). Antibiotic Resistance Patterns and Association With the Influenza Season in the United States: A Multicenter Evaluation Reveals Surprising Associations Between Influenza Season and Resistance in Gram-Negative Pathogens. Open Forum Infectious Diseases. 9(3). ofac039–ofac039. 8 indexed citations

Wittke, Frederick, Catherine Vincent, James Chen, et al.. (2020). Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid. Antimicrobial Agents and Chemotherapy. 64(10). 42 indexed citations

Peyrani, Paula, Julio A. Ramírez, Wesley H. Self, et al.. (2017). Rationale and Methods of the Study Protocol: Streptococcus pneumoniae Serotypes in Adults 18 Years and Older with Radiographically-Confirmed Community-Acquired Pneumonia (CAP). ThinkIR: The University of Louisville's Institutional Repository (University of Louisville). 1(4). 2 indexed citations

10.

Corey, G. Ralph, Francis F. Arhin, Matthew A. Wikler, et al.. (2016). Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents. 48(5). 528–534. 28 indexed citations

11.

Corey, G. Ralph, Heidi Kabler, Purvi Mehra, et al.. (2014). Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections. New England Journal of Medicine. 370(23). 2180–2190. 226 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact